Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee.

Jang S, Lee K, Ju JH. · 2021

Read Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. by Jang S, Lee K, Ju JH. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7961389.txt.

Introduction

Jang and co-authors present a review of recent updates on osteoarthritis of the knee. The disease wears down joint cartilage and distorts the joint. Pain, swelling, and stiffness follow. It is a major cause of disability, and its rate will climb as populations age and obesity spreads. The review covers diagnosis, disease process, and treatment in light of fresh research.

Cell therapy draws much of the attention. Stem cells from embryos or reprogrammed skin can become cartilage cells. Mesenchymal stem cells are the most studied option for injection into the joint. They can form cartilage-like cells and calm the immune response. Trials of such therapies are summed up in brief. Non-cell treatments get their due as well. The authors say real needs remain unmet despite the gains. The review lays a base for the next round of clinical work.

Catalog record

CREATORJang S, Lee K, Ju JH.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7961389

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee By Sunhee Jang, Kijun Lee, Ji Hyeon Ju, Masato Sato Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms22052619 ABSTRACT Osteoarthritis (OA) is a degenerative and chronic joint disease characterized by clinical symptoms and distortion of joint tissues. It primarily damages joint cartilage, causing pain, swelling, and stiffness around the joint. It is the major cause of disability and pain. The prevalence of OA is expected to increase gradually with the aging population and increasing prevalence of obesity. Many potential therapeutic advances have been made in recent years due to the improved understanding of the underlying mechanisms, diagnosis, and management of OA. Embryonic stem cells and induced pluripotent stem cells differentiate into chondrocytes or mesenchymal stem cells (MSCs) and can be used as a source of injectable treatments in the OA joint cavity. MSCs are known to be the most studied cell therapy products in cell-based OA therapy owing to their ability to differentiate into chondrocytes and their immunomodulatory properties. They have the potential to improve cartilage recovery and ultimately restore healthy joints. However, despite currently available therapies and advances in research, unfulfilled medical needs persist for OA treatment. In this review, we focused on the contents of non-cellular and cellular therapies for OA, and briefly summarized the results of clinical trials for cell-based OA therapy to lay a solid application basis for clinical research. 1. INTRODUCTION Osteoarthritis (OA) is the most common chronic articular disease and remains one of the few chronic aging disorders with few effective treatments, none of which have been proven to delay disease progression. It can affect small, medium, and large joints, although in terms of a painful disease, the knee is most frequently affected in up to 10% of men and 13% of women aged above 60 years, with evidence of symptomatic OA of the knee in the United States [1]. OA can be defined pathologically, radiographically, and clinically. The most common method for radiographic definition is the Kellgren–Lawrence (KL) radiographic grading system and atlas, which has been used for more than 40 years. This overall joint scoring system grades OA into five levels from 0 to 4, defining OA by the presence of a definite osteophyte (Grade ≥ 2), and more severe grades by the presumed successive appearance of joint space narrowing, sclerosis, cysts, and deformity [1,2]. However, all patients with radiographic OA do not have a clinical condition, and all patients with joint symptoms do not demonstrate radiographic OA [1]. Therefore, OA must be diagnosed using a variety of pathological, clinical, and radiological methods [3]. 2. OSTEOARTHRITIS OF THE KNEE The knee is the largest synovial joint in humans and consists of bone structures (distal femur, proximal tibia, and patella); cartilage (meniscus and free cartilage); ligaments; infrapatellar fat pad; and synovium. The synovium is responsible for the production of synovial fluid that lubricates and nourishes the vascular cartilage. However, considering the frequent use and high stress on this joint, it is a frequent site of painful conditions, particularly OA [4,5]. Disease evaluation of OA is generally slow and can take years. Successively, the disease can also go through stages or show gradual evolution over time, making the severity and symptoms of the disease worse [6]. 3. MECHANISMS/PATHOPHYSIOLOGY The diarthrodial joint connects two adjacent bones, covered with a special articular cartilage layer, and wrapped in a synovial bursa [7]. The articular cartilage is composed of water (>70%) and organic extracellular matrix components, mainly type II collagen, aggrecan, or other proteoglycans [6]. Chondrocytes detect mechanical stress and changes in the pericellular matrix primarily through receptors on the components of the extracellular matrix. The change in response to mechanical or inflammatory stimulation results in the upregulation of aggrecanase and collagenase. Moreover, receptors on resting chondrocytes are protected from interacting with certain matrix components by the unique composition of the pericellular matrix. Type II collagen-containing networks in the interregional regions are generally not degraded as they are coated with proteoglycans [8]. The main cartilage matrix-degrading enzymes are zinc-dependent metalloproteinases (MMPs) belonging to the MMP and A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) families. MMPs include the collagenases MMP-1 and MMP-13 (highly efficient against type II collagen as a substrate), MMP-3 (a potent aggrecanase), and MMP activator [9]. The importance of proteoglycan depletion in cartilage erosion has been demonstrated in ADAMT5 (the primary aggrecanase) knockout mice protected from progression using a surgical OA model [10]. However, aggrecan depletion, by itself, does not drive OA progression, as suggested by studies wherein MMP13 knockout mice exhibited inhibition of cartilage erosion; however, it does not prevent aggrecan depletion [11]. When the collagen network begins to break down, irreversible cartilage breakdown proceeds [8]. Partly, overloading and inflammation leading to cartilage degradation can cause OA. Prostaglandin E2 is one of the major catabolic factors associated with OA, where MMP is crucial for cartilage degeneration. Thus, the mechanosensitive microsomal prostaglandin E synthase type 1 enzyme represents a potential therapeutic target in OA [12]. In OA, there is a gradual disappearance of cartilage associated with chondrocyte loss and phenotypic transformation, including cluster formation and activation of catabolic phenotypic and hypertrophic differentiation. Remodeling of subchondral bone occurs with the development of blood vessels located in structures (vascular channels) that contain osteoblasts and sensory nerves. Vascular channels should facilitate biochemical communication between the bone and cartilage. In response to multiple stimulations, chondrocytes modify the phenotype and express a subset of factors (such as cytokines, chemokines, alarmins, damage-associated molecular pattern, and adipokines). All these mediators act as paracrine factors, begin a vicious cycle of cartilage breakdown, reach the synovial fluid, and trigger an inflammatory process with the production of synovial macrophages and fibroblasts of the factor [8]. Vascular channels have sensory nerve terminations, and the associated innervation of articular cartilage may contribute to tibiofemoral pain in OA across a wide range of structural disease severities [13]. Figure 1 illustrates the associated mechanism [6,8]. The infrapatellar fat pad (IFP) is in close contact with the synovial membrane, and due to the metabolic properties of adipose tissue, IFP may affect the functioning of the synovial membrane [14]. In a recent study, it was found that IFP in OA patients of the knee was more inflamed and vascularized compared to the IFP in anterior cruciate ligament reconstruction patients [15]. It has been recognized that IFP secretes adipocytokines and has more inflammation and fibrotic changes than control group [15]. All of these studies could support the new idea that the IFP and the synovial membrane could be considered a morpho-functional unit [14]. Cartilage is a highly specialized connective tissue, and its damage is the main feature of OA. The primary determinants of OA are namely, aging, genetic predisposition, metabolic syndrome, or trauma, and activation of the inflammatory pathways occurs in cartilage [16]. Chondrocytes form a vicious cycle leading to the progression of OA by producing inflammatory mediators that can lead to cartilage damage and changes in adjacent joint tissue. Therefore, the components of inflammatory pathways to discover disease-modifying OA drugs should be known [8]. 4. DIAGNOSIS Although OA is an extremely common illness, its diagnosis may be difficult. Diagnostic criteria were developed for OA of the knee. The

Read the complete text